Drug Trial Radar · NCT00838357
A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).
Last checked: Nov 20, 2026Latest source record: Mar 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
118
Actual
Start
Sep 2008
Primary completion
Nov 2010
Study completion Nov 2010
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 6, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a research study intended to further investigate the safety and efficacy of plerixafor in patients with NHL, HD, or MM. Patients who have previously failed stem cell mobilisation attempts or who have previously received more than one autologous or any allogeneic stem cell transplant are not eligible.
Conditions
- Lymphoma (Non-Hodgkin's Lymphoma)
- Hodgkin's Disease or Multiple Myeloma
- Front Line Mobilization
- Transplantation
Interventions
Generic = PlerixaforDrug
240µg/kg administered as an SC injection 10 to 11 hours prior to initiation of apheresis. Daily administration for 1 up to 5 consecutive days
Primary outcomes
What the sponsor says the trial is designed to measure.
- To confirm the safety profile of plerixafor to mobilise stem cells when used in patients with lymphoma or MM who are eligible to undergo treatment with an autologous haematopoietic stem cell transplantTime frame: 24 months
Locations
26 sites in 7 countries. Site status is shown where the registry gives one.
Hôpital du Haut Lévêque
Bordeaux, France
Hôpital Lyon Sud
Lyon, France
Institut Paoli Calmettes
Marseille, France
CHU Hotel-Dieu Université de Nantes
Nantes, France
Hôpital Saint-Louis
Paris, France
Institut Gustave Roussy
Villejuif, France
Charité - Campus Benjamin Franklin
Berlin, Germany
Klinikum der Universität zu Köln
Cologne, Germany
Universitätsklinikum Carl Gustav Carus
Dresden, Germany
Universitätsklinikum Heidelberg
Heidelberg, Germany
Klinikum Nürnberg Nord
Nuremberg, Germany
Universitätsklinik Würzburg
Würzburg, Germany
L. & A. Seragnoli, University of Bologna
Bologna, Italy
Ospedale Ferrarotto
Catania, Italy
Azienda Ospedaliera S. Martino
Genova, Italy
VU Medisch Centrum
Amsterdam, Netherlands
Hospital Santa Creu y Sant Pau
Barcelona, Spain
Hospital Carlos-Haya
Málaga, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
Hospital la Fe
Valencia, Spain
Karolinska Universitetssjukhuset Huddinge
Stockholm, Sweden
Akademiska Sjukhuset
Uppsala, Sweden
Gartnavel Hospital
Glasgow, United Kingdom
St James's University Hospital
Leeds, United Kingdom
King's college Hospital
London, United Kingdom
Nottingham University NHS Trust
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.